8-K: Eli Lilly Q3 2026: Revenue Surges 39%, Guidance Raised

Eli Lilly reported a robust third quarter of 2026 with a 39% revenue increase to $24.4 billion, primarily driven by Mounjaro and Zepbound, and raised its full-year financial guidance.

Summary

• Eli Lilly and Company announced strong third-quarter 2026 financial results, with revenue increasing 39% to $24.4 billion compared to the same period in 2025.
• Earnings per share (EPS) on a reported basis increased 16% to $7.22, and on a non-GAAP basis, EPS increased 7% to $7.48.
• The company raised its full-year 2026 revenue guidance to a range of $91.0 to $92.0 billion and increased its non-GAAP EPS guidance midpoint by $4.07, now projected between $35.00 to $36.00.
• Key drivers for revenue growth included Mounjaro and Zepbound, with significant contributions from oncology, immunology, and neuroscience products.
• The quarter included approximately $900 million in benefits, primarily from Jardiance milestones and favorable adjustments to rebate and discount estimates.
• Significant business development activity occurred, including the acquisition of AtaiBeckley and Merida Biosciences.
• Several regulatory approvals and expanded indications were achieved, including for Mounjaro, Onswik, Inluriyo with Verzenio, and Jaypirca.
• Pipeline highlights include positive Phase 3 results for retatrutide and Ebglyss, and Phase 2 results for EloraTZP.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong revenue growth, increased guidance, and significant regulatory and pipeline advancements.

Positives

• Revenue increased by a substantial 39% to $24.4 billion in Q3 2026, driven by strong demand for Mounjaro and Zepbound.
• Full-year revenue guidance was raised by $5.5 billion at the midpoint, now projected between $91.0 to $92.0 billion.
• Non-GAAP EPS guidance was raised by $4.07 at the midpoint, with a new range of $35.00 to $36.00.
• Key product revenue grew to $17.1 billion, with Mounjaro and Zepbound leading the growth.
• Revenue in the Immunology, Oncology, and Neuroscience areas doubled compared to Q3 2025.
• Gross margin increased 40% to $20.5 billion, with gross margin as a percentage of revenue improving to 83.9%.
• Multiple regulatory approvals and expanded indications were secured for key drugs, enhancing market access and therapeutic reach.
• Positive clinical trial results were reported for several pipeline candidates, including retatrutide and EloraTZP, indicating strong future potential.

Negatives

• Reported and non-GAAP EPS included significant acquired IPR&D charges of $4.57 in Q3 2026, compared to $0.71 in Q3 2025, impacting reported earnings.
• Realized prices decreased by 15% globally, primarily due to pricing pressures and adjustments for rebates and discounts, particularly for Zepbound in the U.S. and Mounjaro in China.
• The effective tax rate increased to 23.3% in Q3 2026 from 22.8% in Q3 2025, partly due to the unfavorable tax impact of nondeductible acquired IPR&D charges.
• Acquired IPR&D charges of $4.2 billion were recognized in Q3 2026, significantly impacting net income and EPS on a reported basis.

Risks

• Intense competition affecting the company's products, pipeline, or industry.
• Continued pricing pressures and the impact of governmental and private actors affecting pricing, reimbursement, and patient access.
• Uncertainty and costs associated with pharmaceutical research and development, including regulatory approval processes and clinical trial outcomes.
• The impact and uncertain outcome of acquisitions and business development transactions.
• Potential supply chain disruptions, manufacturing difficulties, or shortages.
• Expiration of intellectual property protection and competition from generic and biosimilar products.
• Risks related to information technology systems, security breaches, and data protection.
• Global macroeconomic conditions, trade disputes, and geopolitical uncertainties.

Future Outlook

The company raised its full-year 2026 revenue guidance to a range of $91.0 to $92.0 billion and increased its non-GAAP EPS guidance midpoint by $4.07, now projected between $35.00 to $36.00. This updated guidance reflects strong underlying performance and business development activities, though it is partially offset by significant acquired IPR&D charges.

Management Comments

• "Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook," said David A. Ricks, Lilly chair and CEO.
• "Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience."
• "To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia."
• "Lilly is executing well across the value chain, and our potential for impact on human health continues to expand."

Industry Context

StockSavvy.ai notes that Eli Lilly's performance, particularly with Mounjaro and Zepbound, aligns with broader industry trends of increasing demand for innovative treatments in diabetes and obesity. The company's significant investments in R&D and business development reflect a competitive strategy to maintain leadership in these high-growth therapeutic areas.

Comparison to Industry Standards

• Eli Lilly's Q3 2026 revenue growth of 39% significantly outpaces the average revenue growth for large pharmaceutical companies, which typically ranges from low to mid-single digits.
• The company's reported EPS growth of 16% and non-GAAP EPS growth of 7% demonstrate strong operational performance, though the impact of acquired IPR&D charges is a notable factor.
• The raised full-year revenue guidance of $91.0-$92.0 billion positions Lilly favorably against competitors, indicating robust market penetration and demand for its key products.
• The company's R&D spending as a percentage of revenue (17% in Q3 2026) is consistent with or slightly higher than industry benchmarks for major pharmaceutical firms, reflecting a commitment to pipeline development.

Management Changes

Legal Proceedings

• Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market.

Stakeholder Impact

• Shareholders: Positive impact expected from increased revenue, raised guidance, and strong pipeline, potentially leading to stock price appreciation.
• Employees: Continued investment in manufacturing and R&D may lead to job creation and growth opportunities.
• Customers (Patients): Access to new and improved treatments through regulatory approvals and pipeline advancements.
• Suppliers: Increased production demands may benefit suppliers of raw materials and manufacturing services.
• Creditors: Strong financial performance and raised guidance suggest continued ability to meet debt obligations.

Next Steps

• Continue to invest in drug-making and technology capabilities.
• Execute on business development deals and partnerships.
• Expand manufacturing capacity in Texas and Virginia.
• Initiate Phase 3 trials for EloraTZP in Q4 2026.
• Continue to advance therapies for treatment-resistant depression and other mental health conditions through AtaiBeckley acquisition.
• Advance treatments for serious autoimmune and allergic diseases through Merida Biosciences acquisition.

Key Dates

Recommendation

The filing demonstrates exceptionally strong financial performance with significant revenue growth and raised full-year guidance, driven by blockbuster drugs like Mounjaro and Zepbound. Coupled with a robust pipeline, multiple regulatory approvals, and strategic acquisitions, Eli Lilly presents a compelling investment case with substantial upside potential.

Keywords

Mounjaro, Zepbound, Tirzepatide, Diabetes, Obesity, Pharmaceuticals, Revenue Growth, Financial Results